Life Sciences

We provide commercial strategy, M&A due diligence, segmentation and resource allocation, and software solutions to companies operating across the broader Life Sciences landscape - including human medical devices (MedTech), human pharmaceuticals, consumer health, and vision health. Our work supports global manufacturers, mid-cap specialists, and private equity-backed Life Sciences companies in answering the commercial questions that drive growth: where to compete, how to position, how to launch, how to size and deploy commercial resources, and how to evaluate acquisition or divestment opportunities.

We work across human MedTech (including advanced medical imaging, surgical instruments, implantable devices, and digital health and telemedicine solutions), human pharmaceuticals (covering primary care, specialty, and hospital products), consumer health (over-the-counter medicines, self-care, and wellness brands), and vision health (ophthalmic devices, surgical eye care, and vision correction). Each sub-sector has distinct commercial dynamics, and our advisors bring sector-specific experience rather than applying a generalist consulting playbook.

MedTech and pharma share many strategic frameworks but differ in critical commercial dimensions. MedTech typically involves capital equipment cycles, hospital purchasing committees, clinical adoption curves, and procedure volume dynamics, whereas pharma centers on prescriber behavior, payer dynamics, market access, and brand-versus-generic lifecycle management. Effective commercial strategy in each requires fluency in those underlying mechanics - for example, designing a launch plan for a surgical instrument requires very different commercial logic from launching a specialty therapeutic, even when the broader strategic question is the same.

Sales territory design is the process of structuring sales territories so that field force capacity is aligned with true customer potential, workload is balanced across reps, and coverage gaps are eliminated. In Life Sciences, where commercial resources are often the largest controllable cost block, well-designed territories can drive meaningful improvements in productivity, growth, and rep retention. Powered by our proprietary AlignMix software, we have led territory redesign engagements for global MedTech and pharma companies covering hundreds of territories across Europe, North America, and other major markets.

We provide commercial due diligence (CDD and VDD), target scouting, acquisition landscape assessments, and post-acquisition value creation support to Life sciences companies and the private equity firms investing in them. Our work spans evaluating individual asset acquisitions, supporting platform investments and buy-and-build strategies, and helping recently acquired portfolio companies translate the deal thesis into measurable commercial results through 100-day plans, pricing transformation, and sales force effectiveness work.

Consumer health covers over-the-counter (OTC) medicines, self-care products, vitamins and supplements, and wellness brands - products typically purchased by consumers without a prescription, often through pharmacy retail, mass retail, and increasingly direct-to-consumer e-commerce channels. Unlike prescription pharma, consumer health depends on brand equity, retail execution, shopper marketing, and channel economics rather than prescriber promotion and payer access. Commercial strategy in consumer health borrows from FMCG playbooks while retaining the regulatory and clinical foundations of pharmaceuticals.